Globus Medical, Inc. (GMED)
| Market Cap | 12.31B |
| Revenue (ttm) | 2.94B |
| Net Income (ttm) | 537.87M |
| Shares Out | 135.67M |
| EPS (ttm) | 3.92 |
| PE Ratio | 23.15 |
| Forward PE | 20.29 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 706,256 |
| Open | 93.94 |
| Previous Close | 93.70 |
| Day's Range | 90.64 - 94.20 |
| 52-Week Range | 51.79 - 101.40 |
| Beta | 1.09 |
| Analysts | Buy |
| Price Target | 100.42 (+10.67%) |
| Earnings Date | May 7, 2026 |
About GMED
Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractu... [Read more]
Financial Performance
In 2025, Globus Medical's revenue was $2.94 billion, an increase of 16.65% compared to the previous year's $2.52 billion. Earnings were $537.87 million, an increase of 422.28%.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for GMED stock is "Buy." The 12-month stock price target is $100.42, which is an increase of 10.67% from the latest price.
News
Globus Medical Schedules First Quarter Earnings Release and Conference Call
AUDUBON, Pa., April 16, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the first quarter ended March 3...
Globus Medical Announces Board Departure
AUDUBON, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced that John A. DeFord, PhD, a Director of Globus Medical I...
Globus Medical Earnings Call Transcript: Q4 2025
Delivered record 2025 results with 16.7% revenue growth and 30.8% non-GAAP EPS growth, driven by strong U.S. spine, enabling tech, and trauma segments. 2026 guidance raised for EPS, with continued margin expansion, robust product launches, and successful integration of NuVasive and Nevro.
Globus Medical Reports Fourth Quarter and Full Year 2025 Results
AUDUBON, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology solutions company, today announced its financial results for the fourth quarter ...
Globus Medical Schedules Fourth Quarter and Full Year 2025 Earnings Release and Conference Call
AUDUBON, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full-year ...
Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results
AUDUBON, Pa., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth quart...
Globus Medical Stock Soars After Earnings. Where It's Seeing the Strength.
Shares of the medical technology company are headed for their largest same-day percentage increase on record.
Globus Medical Earnings Call Transcript: Q3 2025
Q3 2025 saw record revenue, EPS, and free cash flow, led by strong U.S. spine and trauma growth, with Nevro integration ahead of schedule and accretive to earnings. Guidance for 2025 was raised for both revenue and EPS, reflecting confidence in continued profitable growth.
Globus Medical Reports Third Quarter 2025 Results
AUDUBON, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30...
Is Wall Street Underestimating Globus Medical Stock's Potential?
Here's why we believe Globus Medical (GMED) stock merits attention as a value stock. It's currently trading approximately 33% below its 1-year high and is also trading at a PS multiple that falls belo...
Globus Medical Schedules Third Quarter Earnings Release and Conference Call
AUDUBON, Pa., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the third quarter ended Septembe...
Globus Medical Launches ANTHEM™ Elbow Fracture System: A Comprehensive Plating Portfolio for Complex Elbow Trauma
AUDUBON, Pa., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, has announced the launch of the ANTHEM™ Elbow Fracture System, a fully c...
Globus Medical, Inc. Secures Jury Verdict in Delaware Patent Litigation Against Life Spine, Inc.
AUDUBON, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, announced that a Delaware jury has returned a verdict in favor of Globu...
Globus Medical Earnings Call Transcript: Q2 2025
Q2 2025 saw 18.4% revenue growth and 14.1% non-GAAP EPS growth, driven by strong U.S. spine and trauma performance, successful Nevro integration, and robust product innovation. Guidance for 2025 is reaffirmed, with continued focus on operational excellence and market share gains.
Globus Medical Reports Second Quarter 2025 Results
AUDUBON, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended June 30, 202...
Globus Medical Announces Leadership Transitions and Preliminary Second Quarter 2025 Sales Results
AUDUBON, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced that Keith Pfeil, Executive Vice President, Chief Opera...
Globus Medical Schedules Second Quarter Earnings Release and Conference Call
AUDUBON, Pa., July 17, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the second quarter ended June 30...
Globus Medical Introduces DuraPro™ with Navigation, a Next-Generation, Oscillating System Designed to Safeguard Delicate Tissue
AUDUBON, Pa., July 15, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced the expanded Excelsius™ navigation capabilities of its n...
Globus Medical Announces $500 Million Share Repurchase Program
AUDUBON, Pa., May 15, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced that its Board of Directors has authorized a share repurc...
Medical, Inc. Company Investigated by the Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses
Globus Medical Earnings Call Transcript: Q1 2025
Q1 2025 saw flat sales and a 1.4% revenue decline, but profitability and free cash flow hit record highs. The company returned to debt-free status, completed the Nevro acquisition, and reaffirmed 2025 sales guidance, with Q2 already showing recovery as supply chain issues ease.
Globus Medical Reports First Quarter 2025 Results
AUDUBON, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 202...
Globus Medical completes acquisition of Nevro Corp.
AUDUBON, Pa., April 03, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced the completion of its previously disclosed acquisition...
NEVRO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nevro Corp. - NVRO
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Nevro...
Globus Medical extends versatility of Advanced Materials Science™ anterior interbody portfolio with launch of COHERE™ ALIF Spacer and Modulus™ ALIF Blades
AUDUBON, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced two commercial launches: COHERE™ ALIF Spacer: The firs...